Welcome to our dedicated page for Aptose Bioscienc news (Ticker: APTO), a resource for investors and traders seeking the latest updates and insights on Aptose Bioscienc stock.
Aptose Biosciences Inc. (APTO) generates a steady flow of news as a clinical-stage precision oncology company focused on acute myeloid leukemia (AML) and other myeloid malignancies. Company press releases emphasize the development of its lead oral kinase inhibitor tuspetinib (TUS), particularly in a triple drug frontline regimen with venetoclax (VEN) and azacitidine (AZA) for newly diagnosed AML patients who are ineligible for induction chemotherapy.
On this page, readers can follow Aptose announcements on the TUSCANY Phase 1/2 trial, which evaluates the TUS+VEN+AZA triplet. Recent updates describe dose-escalation decisions, safety reviews, and early clinical outcomes such as complete remissions and measurable residual disease (MRD)-negative responses in patients with challenging mutational profiles, including TP53‑mutated/complex karyotype AML and FLT3‑wildtype AML. These releases also discuss the absence of dose-limiting toxicities at reported dose levels and the maintenance of standard-of-care dosing for venetoclax and azacitidine.
Beyond clinical data, Aptose news items cover corporate and regulatory developments, such as financing arrangements, a reverse share split, a committed equity facility, and at‑the‑market (ATM) programs designed to support ongoing clinical work. The company also reports on collaborations, including a Cooperative Research and Development Agreement with the U.S. National Cancer Institute for tuspetinib in myeloMATCH trials, and licensing and financing relationships with Hanmi Pharmaceutical related to tuspetinib.
Investors and observers can use this news feed to track trial milestones, safety and efficacy updates, capital markets actions, auditor changes, and listing status disclosures. Bookmark this page to monitor how Aptose’s tuspetinib-based programs and related corporate activities evolve over time.
Aptose Biosciences reported a net loss of $24.3 million for Q4 2021 and $65.4 million for the year, both increased compared to 2020. The company announced successful clinical results for HM43239, an oral kinase inhibitor, with expanding treatable acute myeloid leukemia (AML) populations following new complete remissions at the 120mg dose. Cash reserves stand at $79.1 million, supporting operations through Q4 2023. The company is advancing HM43239 into broader clinical trials in 2H2022. A conference call is scheduled for today to discuss these results and updates.
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS) announced it will release financial results for the year and quarter ended December 31, 2021, on March 22, 2022, post-market close. The report will include a corporate update. A conference call is scheduled for the same day at 5:00 PM ET, accessible via dial-in and webcast. Key products in Aptose's pipeline include two oral kinase inhibitors aimed at treating hematologic malignancies, currently undergoing various clinical trials.
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS) announced its participation in Oppenheimer’s 32nd Annual Healthcare Conference on March 15, 2022. William G. Rice, Ph.D., Chairman, President, and CEO, will present and host one-on-one meetings during the event. The virtual presentation is scheduled from 10:00 to 10:30 ET. Interested parties can access the webcast through Aptose's website or directly via a provided link. Aptose specializes in developing personalized oncology therapies, currently focusing on treatments for hematologic malignancies, including two investigational products in clinical trials.
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) will participate in two key biotech events in January 2022: the H.C. Wainwright BIOCONNECT Virtual Conference (January 10-13) and the 11th Annual LifeSci Partners Corporate Access Event (January 5-7). The management team will host investor meetings at both events. Aptose focuses on developing innovative cancer therapies, with products like HM43239 and luxeptinib aimed at treating hematologic malignancies. For more details, visit www.aptose.com.
Aptose Biosciences Inc. (NASDAQ: APTO) announced the discontinuation of clinical development for APTO-253, following an internal review and a clinical hold from the FDA. The focus will shift to advancing their kinome inhibitor pipeline, specifically HM43239 and luxeptinib, which have shown promising clinical activity in hematologic malignancies. The company is exploring strategic alternatives for APTO-253. This decision underlines Aptose's commitment to addressing unmet medical needs in oncology.
Aptose Biosciences has reported promising results for its oral myeloid kinome inhibitor HM43239, presented at the 2021 ASH Annual Meeting. The drug showed durable activity in patients with relapsed or refractory acute myeloid leukemia (AML). Key highlights include a 37.5% complete response rate among FLT3 mutant patients at the 80 mg dose. The Phase 1/2 trial enrolled 34 patients, showing a favorable safety profile. Additionally, data for luxeptinib and APTO-253 were shared, showcasing their potential in treating hematologic malignancies. Aptose aims to expand its clinical portfolio significantly.
Aptose Biosciences Inc. (NASDAQ: APTO) provided an update on its clinical developments on November 29, 2021, ahead of its corporate presentation on December 13, 2021. The presentation will highlight data from the oral Phase 1/2 trial of HM43239, an oral myeloid kinome inhibitor targeting relapsed or refractory acute myeloid leukemia (AML). Additionally, the status of luxeptinib, a dual lymphoid and myeloid kinome inhibitor, will be discussed. Both compounds are part of Aptose's continued commitment to advancing therapies for unmet needs in oncology.
Aptose Biosciences (Nasdaq: APTO; TSX: APS) announced its participation in the virtual Piper Sandler 33rd Annual Healthcare Conference, scheduled from November 23 to December 2, 2021. The company will present a pre-recorded fireside chat, which will be accessible on the conference website and through Aptose's official site. Additionally, management will engage in 1-on-1 investor meetings during the event. Aptose focuses on personalized oncology therapies, with a pipeline that includes three clinical-stage products targeting hematologic malignancies.
Aptose Biosciences reported a net loss of $11.3 million for Q3 2021, a decrease from $13.2 million in Q3 2020. Total cash as of September 30, 2021, was $95.1 million, projected to fund operations into early 2023. The company advanced its pipeline with HM43239, a myeloid kinome inhibitor, and increased the dose of Luxeptinib in ongoing clinical trials. Significant reductions in general and administrative expenses were observed. Aptose plans a conference call at 5 PM ET today to discuss these results.
Aptose Biosciences (NASDAQ: APTO) announced the acceptance of clinical data for its myeloid kinome inhibitor HM43239 for oral presentation at the 63rd ASH Annual Meeting in December 2021.
Additionally, data for Luxeptinib and APTO-253 have been accepted for poster presentations. The oral presentation is scheduled for December 13, 2021, while poster presentations will occur on December 11 and 13.
The presentations will feature new data and an investor event will provide further details.